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Asthefirststepintheprocessofcarcinogenesis, mostchemical carcinogensrequiremetabolicactivation by
cytochromes P450 for conversion to highly reactive electrophiles that bind covalently to DNA. Studies in
rodentssuggestthatloworhighlevels ofexpressionofasingleP450candeterminesusceptibilityorresistance
to chemically induced cancer. Although rodent systems have been used to explore the molecular basis of
chemical carcinogenesis andto identifychemicals capable ofdamaging genes and causingcancer, it has been
understood that marked species differences exist in the expression, regulation, and catalytic activities of
different P450s. Thus, large efforts are underway to study the catalytic activities ofhuman P450s directly by
expression of their cDNAs in cultured cells. Two systems are being used: a) transient high-level P450
production in HepG2 cells for analysis ofcatalytic activities, and b) stable expression in human B-lympho-
blastoid cells to study promutagen and procarcinogen activation. These studies define the relative contribu-
tions ofindividual P450forms tothe activation ofvariouschemical carcinogens. The B-lymphoblastoidcDNA
expressionsystem canalsobeusedtodeterminewhetherachemicalwillbehazardousortoxictohumans.The
most intriguing aspects of P450s are the occurrence of human genetic polymorphisms in P450 expression,
which could be a risk factor for chemical carcinogenesis. The best-studied P450 genetic polymorphism is the
debrisoquine/sparteine polymorphism which is due to mutant CYP2D6 alleles. Four mutant alleles have been
characterized that account for most ofthe defective CYP2D6 genes in Caucasians. These can be detected by
polymerase chain reaction assays. The expression ofother P450s is currently being studied in human tissue
specimens to determine whether functional polymorphisms exist with other P450 forms.
Properties, Organization, and
Nomenclature of Cytochromes P450
As a group, cytochromes P450 (P450) rangein sizefrom
about 48 to 60 kDa and contain a single molecule of
noncovalentlyboundheme.AllP450s use 02 and electrons,
usuallyfrom NADPH, to oxidize substrates byproduction
of an activated oxygen. The region of the P450 primary
sequence thatcontains thethiolate fifthligandtotheheme
iron (1) is highly conserved (2). This sequence ofabout 26
residues could be considered a "fingerprint" for a P450
protein.
Three general classes of P450s exist: a) soluble forms
with high substrate specificity found in bacteria; b) those
involved in highly specific steroid hydroxylations, some of
which are located in the inner mitochrondrial membrane
(encoded by nuclear DNA); and c) those bound to the
endoplasmicreticulumofthecell,which,byandlarge, have
broad substrate specificities. Some oftheseP450s activate
chemical carcinogens to their proximate electrophilic
forms which can bind covalently to DNA.
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P450shavebeenorganized onthebasisofsimilaritiesin
protein sequence, and a nomenclature system has been
developed (3). The "P450 superfamily" is subdivided into
families; individual P450s within a family are defined as
having<40% sequence similaritywith aP450in anyother
family. Families are further divided into subfamilies: all
P450swithin a subfamily are >55% similar in sequence.
P450s are named using the root symbol CYP (Cyto-
chrome P450), followed by anArabic numeral designating
the family number, a letter denoting the subfamily, and
anotherArabic numeral representing the individual gene.
Thus,CYPlAl isP450form1intheAsubfamilyoffamily1.
Namesofgenesarewritteninitalics, CYPlAl. Itshouldbe
emphasized that the nomenclature system is based solely
on sequence similarity amongP450s and does notindicate
the properties or function of individual P450s. Circum-
stantially, however, the steroidogenic P450s fall into fami-
lies distinct from those of the foreign compound
metabolizing enzymes. The latter fall almost exclusively
into mammalian families, CYPl, CYP2, CYP3, and CYP4.
Because ofthe diverse catalytic activities ofthe foreign
compound metabolizing P450s, it has been difficult to
identifyorthologous P450 counterparts amongspecies (an
orthologous P450 gene in two species is one that shared a
common ancestor before evolutionary divergence of the
two species); this has complicated P450 nomenclature. Of
the foreign compound metabolizing P450s, only CYPlAl
and CYP1A2 have unequivocal orthologous counterpartsGONZALEZ AND GELBOIN
in all animal species examined. Individual P450s within a
subfamily are designated by different numbers: for exam-
ple, rats possess CYP2D1 through CYP2D5, humans
CYP2D6 through CYP2D8, and mice CYP2D9 through
CYP2D13.
Evolution of P450s and Species
Differences
P450s are believed to have evolved from a common
ancestor about 3 billion years ago (4). The earliest P450s
probablyexistedtometabolize steroids such ascholesterol
in order to maintain membrane integrity, and several
P450s continued through the course of evolution to func-
tion in steroid biosynthesis and metabolism. Only more
recently (during the last 100-500 million years) have
P450s taken onthe role ofriddingthe organism offoreign
compounds. Numerous gene duplications have occurred
during the past 200 million years; most importantly, new
P450geneswereformedincertainspeciesandsomelostin
otherspecies.Thisprocessisbestillustratedbyexamining
thecomplexityoftheCYP2Dgenesinrodentsandhumans
(5). Ratsandmicepossessfivegenes,allofwhichappearto
be normal, whereas humans have one active gene and two
pseudogenes. The rodent genes have also undergone
numerous "homogenizing" gene conversion events, so that
no orthologous counterpart of any single rat gene can be
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identifiedin mice. Otherevents, in additionto gene conver-
sion, that occur in a species-specific manner, possibly due
to environmental influences, have resulted in catalytic
activities and regulatory circuits that can be unique to a
given animal.
It is not currently understood what environmental fac-
tors give rise to the battery ofP450s in an animal or, at a
more basic level, how and why foreign compound meta-
bolizing P450s have arisen. One possibility is that these
enzymes evolved as a defense against toxins found in the
food chain, particularlyinplants, inwhich alarge number
oftoxinshasbeendeveloped,probablyasadefenseagainst
predators. New P450s thus appeared in response to plant
toxins or new plant varieties or as a means of exploiting
newsourcesofvegetation. Conversely,when aplantsource
is nolongeravailable, certainP450smightdisappearfrom
the gene pool. Indeed, the entire CYP2D locus appears to
be vanishing in humans (5).
The consequences of P450 evolution are species dif-
ferences and genetic polymorphisms. Species differences
in P450s havemeantthatbetterfocus and directexamina-
tion of human enzymes and less reliance on data from
rodents are required to predict the adverse effects of
chemicals. P450 polymorphisms have had a direct impact
on the development ofdrugs in the pharmaceutical indus-
try,because certainestablished P450formsclearlyexhibit
genetic differences and are known to metabolize and gen-
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aPartial list ofpreferred substrates for each P450; a more complete compilation is given by Guengerich and Shimada (6).
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erally inactivate therapeutic agents. The extent of P450
polymorphisms in humans is also being evaluated with a
view to diagnostic analysis ofmutant human P450 genes,
to investigate whether the presence or absence ofa P450
involved in activation or inactivation of a carcinogen
resultsinanincreasedriskoforprotectionagainstcancer.
cDNA Expression of Human P450s
and Risk Assessment
Human P450s can be studied directly after isolation
from tissues such as liverbyreconstitutionwith NADPH-
P450 oxidoreductase and analysis oftheir catalytic activi-
ties in the tissue or in microsomal extracts, using immu-
nochemicalapproaches. Thesetypesofinvestigationshave
led to determination ofsubstrate specificities ofindividual
P450 forms and the role of specific P450s in total liver
microsomal metabolism ofspecific procarcinogens (6).
cDNA expression has also been used to study human
P450 catalytic activities. Ithasbeenrelativelystraightfor-
ward to isolate human P450 cDNAs from cDNA libraries
constructed from liver and lung tissue RNA, using anti-
bodies and cDNA probes against different rodent P450
forms. Human P450s thathavebeenisolated to date, their
tissue-specific expression, whether a rodent counterpart
exists, and a typical substrate are listed in Table 1. Two
cDNAs, CYPlA1 and CYP1A2, were isolated from human
cells andliverlibraries, respectively, andapparentlyshare
enzymatic properties with their rodent counterparts. At
leastnine cDNAsthatencode active enzymes inthe CYP2
family have also been isolated. One form, CYP2F1,
appears to be expressed preferentially in extrahepatic
tissues. Of these cDNA-expressed forms, only CYP2E1
exhibits catalytic activities that are similar to those ofrat
and rabbit CYP2E1. Four distinct CYP3A P450 cDNAs
were isolated from human liver, one ofwhich is expressed
only in the fetus. Only two CYP3A P450s have been
described in rat, and one in rabbit. All CYP3A P450s
exhibit testosterone 6,B-hydroxylase activities, but ac-
tivities toward other substrates may differ. To date, no
P450hasbeendemonstratedinthe CYP4family, although
they are known to exist.
Human cDNA-expressed P450s can be examined for
theirabilities toactivatepromutagens andprocarcinogens
usingthreeprotocols: a) direct assayofactivemetabolites
by analytical separation; b) an Ames test assay in which
human P450s are substituted for the standard Aroclor-
induced rat liver extracts; and c) in-situ DNA binding
assays in cells that express human P450s.
The Ames test has been used to evaluate the role of
differenthumanP450sintheactivation ofthecookedfood-
derived mutagen, 2-amino-3-methylimidazo [4,5-Jlquin-
oline (IQ), by cDNA-expressed human liver P450 (20).
CYP1A2, an enzyme expressed constitutively in liver and
not in extrahepatic tissues, was the most active, followed
by P450s in the CYP3 family which are expressed in
several extrahepatic tissues. Food mutagens are typically
carcinogens in nonliver tissue (27), although they are
potent hepatocarcinogens in nonhuman primates (28).
These compounds might be activated in the liver and extra-
hepatically by CYPLA2 and the CYP3 P450s, respectively.
Aflatoxin B1 activationwasmeasuredbyDNAbindingin
situ in an experiment in which cells that express different
forms ofhuman P450 in culture were incubated with radio-
labeledcarcinogens; DNA-boundcarcinogenwasthendeter-
mined (29). Five human P450 forms were found to catalyze
DNA binding, while another seven forms were inactive.
These five forms were also active in aflatoxin B1 muta-
genesis, as measured in the Ames test; however, the condi-
tions oftheexperiment did notdistinguishthoseP450swith
high affinity for aflatoxin B1 from low-affinityforms.
Metabolic activation by human P450s of a rodent and
ruminant pneumotoxin, 4-ipomeanol, was also evaluated
(30). Surprisingly, the primary human lung P450s
CYP2F1 and CYP4B1 were unable to activate this com-
pound; in contrast, rabbit CYP4B1 and human CYP1A2, a
nonpulmonary P450, were active. These data indicate a
marked species difference in the catalytic activity of one
P450.
Human P450s have also been expressed using a B-lym-
phoblastoid cell line, AHH-1, with herpes virus-based
vectors. A number of P450s have been accurately
expressedusingthis system,includingCYP1A2, CYP2A6,
CYP2D6, CYP2E1, and CYP3A4 (Table1). This expressed
system differs from that ofVaccinia, since the P450s are
stably expressed. AHH-1 cells are especially useful for
expressing P450s because they were originally developed
as a eukaryote mutagen testing system (31).
Metabolic activation of aflatoxin B1 was also studied
using cell lines that express individual P450s (9). Cells
were assayed for toxicity and mutagenicity at the hypox-
anthine guanine phosphoribosyl transferase (hprt) locus.
CYPlA2-expressing cells were the most sensitive to the
toxicity andmutagenicityofaflatoxin B1: as little as 10ng/
mLofthecarcinogeninthemediumproducedasignificant
response. CYP3A4-expressing cells were also sensitive to
aflatoxin B1, although about 5- to 10-fold less than
CYPlA2-containingcells.CellsthatexpressCYP2A6were
the least sensitive, and cells with no expressed human
P450wereresistanttothecompound atalevelof1 pLg/mL.
These data suggest that CYPIA2 has the highest activa-
tionactivityforaflatoxinB1 andisprobablytheP450form
that activates the carcinogenunderordinaryconditions of
human exposure.
In a separate experiment, CYP2E1 and CYP2A6 were
compared for their ability to activate the low-molecular-
weight nitrosamines N-nitrosodiethylamine and N-nitro-
sodimethylamine (21). Surprisingly, consideringthe struc-
tural similarities of these two nitrosamines, cells that
express either P450 were sensitive to both chemicals but
CYP2A6-expressing cells were considerably more sensi-
tive to the toxicity and mutagenicity of N-nitrosodi-
ethylamine and CYP2E1-expressing cells were more
sensitive to N-nitrosodimethylamine.
Cells suitable for analyzing diverse classes of car-
cinogens and mutagens should simultaneously express
multipleP450s.This hasbeen accomplished to adegreeby
inserting four P450 cDNAs and epoxide hydratase cDNA
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into acellline. Thesecells, designated MCL-5, arerespon-
sive to small nitrosamines, polycyclic aromatic hydrocar-
bons, and aflatoxin B1 (32) and arepotential prototypes of
cells that could be used to test unknown compounds for
carcinogenicity and mutagenicity.
Interindividual Differences in P450
Expression and Cancer Susceptibility
Early studies in clinical pharmacology established that
marked interindividual differences in P450 expression
exist as a human polymorphism. The clearest example is
the debrisoquine/sparteine drug oxidation genetic poly-
morphism, inwhich 75% ofCaucasians possess two copies
of a mutant CYP2D6 gene and thus cannot metabolize
debrisoquine and a growing number of other clinically
useddrugs (33).Almostallmutantgenescanbediagnosed
by polymerase chain reaction analysis ofleukocyte DNA.
Another drug oxidation polymorphism, associated with
S-mephenytoin and involving a P450 in the CYP2C sub-
family, exists, butithas notbeen elucidated atthemolecu-
lar level.
Epidemiological evidence shows that CYP2D6 expres-
sion is associated with risk for smoking-associated non-
adenocarcinoma of the lung (34). CYP2D6 is capable of
metabolically activating the tobacco smoke-specific nitro-
samine 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-buta-
none (NNK) (18); however, several other P450s are also
capable of activating this compound. Thus, the precise
biochemicalbasis ofthe associationbetween CYP2D6 and
cancer is still unclear.
The question remains whether interindividual dif-
ferences inlevels ofexpression ofotherknowncarcinogen-
activating P450s are associated with increased cancer
risk. Markeddifferences existinthelevelsofexpression of
CYP1A2 (35-37), CYP2A6(10), CYP2B6(11),CYP2E1(38),
and the CYP3AP450s (23), as detected bywesternimmu-
noblot and northern blot analysis of protein and mRNA
isolated from human liver specimens; there is also a large
degree ofvariationinthe expression ofCYPlAl mRNAin
lung samples from smokers and nonsmokers. In order to
establish whether expression ofa P450 is associated with
increased cancer risk, however, cohort and prospective
epidemiological surveys must be conducted. These will be
possible only when accurate, noninvasive assays can be
provided for measuring P450 form-specific activities in
humans. Several candidate compounds that canbe used in
this capacity have been proposed (6) but have yet to be
used in cancer epidemiological studies.
This manuscript was presented at the Conference on Biomonitoring
and Susceptibility Markers in Human Cancer: Applications in Molecular
Epidemiology and Risk Assessment that was held in Kailua-Kona,
Hawaii, 26 October-1 November 1991.
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